Document Type


Publication Date


Publication Title

Oxidative Medicine and Cellular Longevity


Leishmaniasis is a disease that is a significant problem for people, especially in tropical regions of the world. Current drug therapies to treat the disease are expensive, not very effective, and/or of significant side effects. A series of alkyl bisphosphonate compounds and one amino bisphosphonate compound, as well as alendronate and zoledronate, were tested as potential agents against Leishmania tarentolae. Also, two polyoxometalates (POMs) with nitrogen-containing bisphosphonate ligands, vanadium/alendronate (V5(Ale)2) and vanadium/zoledronate (V3(Zol)3), were tested against L. tarentolae and compared to the results of the alendronate and zoledronate ligands alone. Of the compounds evaluated in this study, the V5(Ale)2 and V3(Zol)3 complexes were most effective in inhibiting the growth of L. tarentolae. The V5(Ale)2 complex had a larger impact on cell growth than either alendronate or orthovanadate alone, whereas zoledronate itself has a significant effect on cell growth, which may contribute to the activity of the V3(Zol)3 complex.

Funding Source

The authors thank the Department of Chemistry at Illinois State University, CNRS, and the Universite de Versailles St ´ Quentin for support for this research. They thank Dr. A. Herlinger (Loyola University, Chicago, IL) for the generous gift of the four alkyl bisphosphonates, 1–4.




First published in Oxidative Medicine and Cellular Longevity volume 2016, article ID 9025627.

This work was presented in part at the 9th International Vanadium Symposium, Padova, Italy, June 30–July 2, 2014.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

2016_oxidative_supplementary_figures.pdf (345 kB)
supplementary figures (1395 kB)
supplementary .mov f2 (1859 kB)
supplementary .mov f3

Included in

Chemistry Commons